THE EFFECTIVENESS OF MINIMALLY INVASIVE SURGICAL TREATMENTS WITH REZŪM SYSTEM FOR BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Introduction: Benign prostatic hyperplasia (BPH) is a common chronic condition frequently associated with the progressive development of voiding and obstructive lower urinary tract symptoms (LUTSs). Objective: This research aims to assess the effectiveness of the Rezūm system for BPH. Material & Methods: A literature search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Clinical baseline characteristics, international prostate symptom score (IPSS), maximum flow rate (Qmax), postvoid residual (PVR), and quality of life (QoL) were analyzed using Revman 5.3. The risk of bias assessments was conducted by two independent authors and resolved through discussion. Results: A total of 288 studies were retrieved from PubMed, Cochrane, and Google Scholar. Four studies, including 590 patients, were analyzed, with a follow-up period of up to 12 months after treatment using the Rezūm system. The mean (SD) change from baseline to follow-up in IPSS improved from 20.58 (5.9) to 9.53 (6.7); Qmax increased from 9.2 (3.2) to 13.48 (6.5); PVR decreased from 128.2 (137.8) to 76.0 (88.8); and QoL improved from 4.6 (1.2) to 2.0 (1.4). The greatest improvement was observed in QoL (56.52%) followed by IPSS (55.88%), Qmax (46.74%), and PVR (40.72%). Conclusion: The Rezūm system is an effective therapy for BPH, providing significant relief of LUTSs. Keywords: Benign prostatic hyperplasia, LUTS, Rezūm system
##plugins.themes.bootstrap3.article.details##
Benign prostatic hyperplasia, LUTS, Rezūm system.
Darson MF, Alexander EE, Schiffman ZJ, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159-68.
Cantrill CH, Zorn KC, Elterman DS, Gonzales RR. 2 Cantrill, The Rezum system - a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia. Can J Urol. 2019;26(3):9787-93.
Das AK, Leong JY, Roehrborn CG. Office-based therapies for benign prostatic hyperplasia - a review and update. Can J Urol. 2019;Suppl 1:2-7.
Rassweiler J, Teber D, Kuntz R, et al. Complications of transurethral resection of the prostate (TURP) - incidence, management, and prevention. Eur Urol. 2006;50:968-80.
Dixon C, Cedano ER, Pacik D, et al. Efficacy and safety of rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2015;86(5):1043-47.
Henry H Woo HH, Gonzalez RR. perspective on the rezūm system: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Devices.2017;10:71–80.
McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy (wave) ablation: a multicenter, randomized, controlled study for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2015;10:1-17.
Roehrborn CG, Gange SN, Gittelman MC, et al. Convective radiofrequency water vapor thermal therapy with rezūm system: durable two-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J. Urol. 2017;197(6):1507
Dixon CM, Cedano ER, Mynderse LA, et al. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol. 2015;7:13-18.
Mynderse LA, Hanson D, Robb RA, et al. Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. 2015;86:122-127.
Westwood J, Geraghty R, Jones P, et al. Rezum: a new transurethral water vapor therapy for benign prostatic hyperplasia. Ther Adv Urol. 2018;10(11):327–333.
Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Clinicoecon Outcomes Res. 2018;10:29–43.